NYSEAMERICAN : VNRX

VolitionRx Limited — Company profile

Healthcare · Medical Devices · United States

Last price 0.1953 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 2.77M

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Company profile

VolitionRx Limited, a multi-national epigenetics company, develops blood tests to help detect and monitor a range of cancers, and diseases associated with NETosis in the United States, Europe, and Asia. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets, detects diseases associated with NETosis, such as sepsis; Nu.Q Discover, a solution to profiling nucleosomes. It also provides Nu.Q Cancer for predicting treatment response, monitoring treatment response and disease progression, and amending a patient’s cancer treatment regimen; and Capture-PCR and Capture-Seq, which are isolating and capturing circulating tumor-derived DNA from plasma samples for early cancer detection. VolitionRx Limited is headquartered in Henderson, Nevada.

Details

NameVolitionRx Limited
SectorHealthcare
IndustryMedical Devices
Employees57
CeoCameron Reynolds
CountryUnited States
ExchangeNYSEAMERICAN
Fiscal YearJanuary - December
Reporting CurrencyUSD
IsinUS9286612067
Cusip928661206
Cik0000093314
Sic2835
Stock TypeCommon Stock

Key executives

NameTitle
Cameron Reynolds MBAFounder, Chief Executive Officer, President and Director
Dr. Gaetan Michel Ph.D.Chief Operating Officer
Terig HughesChief Financial Officer and Treasurer
Dr. Jacob Vincent Micallef MBA, Ph.D.Chief Scientific Officer
Nicholas PlummerGroup General Counsel
Louise Batchelor DayGroup Chief Marketing and Communications Officer
Dr. Jasmine Kway Ph.D.Chief Revenue Officer
Gael Forterre M.B.A.Chief Licensing Officer
Rodney Gerard Rootsaert LLBCorporate Secretary

Contact

Address1489 West Warm Springs Road, Suite 110, Henderson, Nevada 89014, United States
Phone512 774 8930
Websitehttps://volition.com